Format

Send to

Choose Destination
Cancer Cell. 2009 Aug 4;16(2):89-90. doi: 10.1016/j.ccr.2009.07.011.

Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.

Author information

1
The Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK. arv22@cam.ac.uk

Abstract

Targeted therapies exploiting specific molecular defects in cancer cells promise to overcome roadblocks in the development of effective anticancer drugs. A recent report in the New England Journal of Medicine on the early clinical evaluation of Olaparib in cancers lacking the BRCA1 or BRCA2 genes exemplifies this promising new trend.

PMID:
19647219
DOI:
10.1016/j.ccr.2009.07.011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center